Oct 2012 $22 M No. 6 $10 to $50 million 16
Ambit Biosciences Corp.: Raise no. 6, Oct 2012 × Investors in this round 16 investors had bought by the notice of Nov 9, 2012: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Ambit Biosciences Corp. as a whole in other filings: see Investors below.
What the notice says
Amount sold $22 M of $45 M offered; $23 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Alan M. Fuhrman · Executive Officer Athena M. Countouriotis · Executive Officer Michael A. Martino · Executive Officer, Director Allan M. Marchington · Director David P. Bonita · Director Faheem M. Hasnain · Director Isai M. Peimer · Director Joseph M. Regan · Director Saiid M. Zarrabian · Director Standish M. Fleming · Director Steven A. Elms · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Alan Fuhrman, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 9, 2012. Read the notice at the SEC .
equity, options SEC May 2012 $7 M No. 5 $2 to $10 million 16
Ambit Biosciences Corp.: Raise no. 5, May 2012 × Investors in this round 16 investors had bought by the notice of May 30, 2012: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Ambit Biosciences Corp. as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $11 M offered; $4 M still to sell
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Alan M. Fuhrman · Executive Officer Athena M. Countouriotis · Executive Officer Michael A. Martino · Executive Officer, Director Allan M. Marchington · Director Faheem M. Hasnain · Director Isai M. Peimer · Director Joseph M. Regan · Director Saiid M. Zarrabian · Director Standish M. Fleming · Director Steven A. Elms · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Alan Fuhrman, Chief Financial Officer. Source: SEC Form D, newest notice filed May 30, 2012. Read the notice at the SEC .
options SEC May 2011 $22 M No. 4 $10 to $50 million 20
Ambit Biosciences Corp.: Raise no. 4, May 2011 × Investors in this round 20 investors had bought by the notice of Jul 11, 2011: 20 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Ambit Biosciences Corp. as a whole in other filings: see Investors below.
What the notice says
Amount sold $22 M of $30 M offered; $8 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Alan J. Fuhrman · Executive Officer Alan J. Lewis, Ph.D. · Executive Officer, Director Christopher J. Morl · Executive Officer Allan M. Marchington · Director Faheem J. Hasnain · Director Isai J. Peimer · Director Joseph J. Regan · Director Saiid J. Zarrabian · Director Standish M. Fleming · Director Steven J. Elms · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes $26,583.86 receivable by the Comp. upon the exercise of Warrants to purchase up to 26,583,858 shares of Company's Series D-2 Preferred Stock at a purchase price of $0.001, assuming no cashless exercise. Such Warrants have not yet been exercised.”Signed by Alan Fuhrman, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 11, 2011. Read the notice at the SEC .
equity, options SEC Sep 2010 $15 M No. 3 $10 to $50 million 18
Ambit Biosciences Corp.: Raise no. 3, Sep 2010 × Investors in this round 18 investors had bought by the notice of Oct 15, 2010: 18 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Ambit Biosciences Corp. as a whole in other filings: see Investors below.
What the notice says
Amount sold $15 M of $16 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Alan J. Lewis, Ph.D. · Executive Officer, Director Christopher J. Morl · Executive Officer Wendell J. Wierenga, Ph.D. · Executive Officer Alexander J. Zukiwski · Director Allan M. Marchington · Director Joseph J. Regan · Director Saiid J. Zarrabian · Director Standish M. Fleming · Director Steven J. Elms · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes $912,976.68 receivable by the Company upon the exercise of Warrants to purchase up to 592,842 shares of Company's Common Stock at a purchase price of $1.54, assuming no cashless exercise. Such Warrants have not yet been exercised.”Signed by Christopher J. Morl, Chief Business Officer. Source: SEC Form D, newest notice filed Oct 15, 2010. Read the notice at the SEC .
debt, options SEC Mar 2010 $12 M No. 2 $10 to $50 million 2
Ambit Biosciences Corp.: Raise no. 2, Mar 2010 × Investors in this round 2 investors had bought by the notice of Apr 15, 2010: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Ambit Biosciences Corp. as a whole in other filings: see Investors below.
What the notice says
Amount sold $12 M of $13 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Alan J. Lewis, Ph.D. · Executive Officer, Director Kerry A. Kelly, J.D. · Executive Officer Wendell J. Wierenga, Ph.D. · Executive Officer Alexander J. Zukiwski · Director Allan M. Marchington · Director Joseph J. Regan · Director Saiid J. Zarrabian · Director Standish M. Fleming · Director Steven A. Elms · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes amount receivable upon the exercise of Warrants to purchase i) up to 284,584 shares of Series D Preferred Stock at purchase price of $5.06 or ii) up to an undetermined number of shares of preferred stock at an undetermined purchase price.”Signed by Kerry A. Kelly, J.D., Vice President and General Counsel. Source: SEC Form D, newest notice filed Apr 15, 2010. Read the notice at the SEC .
debt, options SEC Jun 2009 $6 M No. 1 $2 to $10 million 13
Ambit Biosciences Corp.: Raise no. 1, Jun 2009 × Investors in this round 13 investors had bought by the notice of Jun 29, 2009: 13 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Ambit Biosciences Corp. as a whole in other filings: see Investors below.
What the notice says
Amount sold $6 M of $20 M offered; $13 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice M. Scott Salka · Executive Officer, Director Wendell Wierenga, Ph.D. · Executive Officer Alan J. Lewis, Ph.D. · Director Alexander Zukiwski · Director Allan Marchington · Director Saiid Zarrabian · Director Standish M. Fleming · Director Steven Elms · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “*Includes approximate amounts receivable by the Company upon the exercise of Warrants to purchase up to 2,039,521 shares of the Company's Common Stock at a purchase price of $0.91, assuming no cashless exercise. Such Warrants have not yet been exercised.”Signed by M. Scott Salka, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 29, 2009. Read the notice at the SEC .
debt, options SEC